(Total Views: 644)
Posted On: 06/23/2022 4:19:50 PM
Post# of 154438
What we take into the weekend:
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1)
“We wish to thank our entire NASH team led by Dr. Recknor, who has done a phenomenal job conducting this study. We are very excited about these results and the potential for helping the millions of individuals effected by NASH across the world. The main focus after seeking approval in the U.S. will be the UK, Canada, Brazil, and the Philippines. Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique
drug with tremendous opportunities.”
My guess, PR tomorrow about NASH, announcement of partnership in CC.
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1)
“We wish to thank our entire NASH team led by Dr. Recknor, who has done a phenomenal job conducting this study. We are very excited about these results and the potential for helping the millions of individuals effected by NASH across the world. The main focus after seeking approval in the U.S. will be the UK, Canada, Brazil, and the Philippines. Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique
drug with tremendous opportunities.”
My guess, PR tomorrow about NASH, announcement of partnership in CC.
(3)
(1)
